Evaluation of the effect of food on the pharmacokinetics of axitinib in healthy volunteers

被引:0
作者
Yazdi K. Pithavala
Ying Chen
Melvin Toh
Paulina Selaru
Robert R. LaBadie
May Garrett
Brian Hee
Janessa Mount
Grace Ni
Karen J. Klamerus
Michael A. Tortorici
机构
[1] Pfizer Inc.,Clinical Pharmacology, Oncology Business Unit
[2] Pfizer Inc.,undefined
来源
Cancer Chemotherapy and Pharmacology | 2012年 / 70卷
关键词
Axitinib; Formulation; Axitinib Form IV FCIR; Axitinib Form XLI FCIR; Food effects; Pharmacokinetics;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:103 / 112
页数:9
相关论文
共 178 条
[1]  
Hu-Lowe DD(2008)Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3 Clin Cancer Res 14 7272-7283
[2]  
Zou HY(2010)Effect of rifampin on the pharmacokinetics of axitinib (AG-013736) in Japanese and Caucasian healthy volunteers Cancer Chemother Pharmacol 65 563-570
[3]  
Grazzini ML(2007)Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study Lancet Oncol 8 975-984
[4]  
Hallin ME(2008)Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study J Clin Oncol 26 4708-4713
[5]  
Wickman GR(2009)Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study J Clin Oncol 27 3836-3841
[6]  
Amundson K(2005)Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results J Clin Oncol 23 5474-5483
[7]  
Chen JH(2012)Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers Invest New Drugs 30 273-281
[8]  
Rewolinski DA(2003)CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment Semin Radiat Oncol 13 176-181
[9]  
Yamazaki S(1999)Effects of food on clinical pharmacokinetics Clin Pharmacokinet 37 213-255
[10]  
Wu EY(2008)Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients Anticancer Drugs 19 275-281